Personal information

Activities

Employment (1)

Hospital Universitario 12 de Octubre: Madrid, Comunidad de Madrid, ES

MD PhD (Medical Oncology )
Employment
Source: Self-asserted source
Manso Luis

Works (50 of 139)

Items per page:
Page 1 of 3

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Journal of Clinical Oncology
2024-12-10 | Journal article
Contributors: Komal L. Jhaveri; Elgene Lim; Rinath Jeselsohn; Cynthia X. Ma; Erika P. Hamilton; Cynthia Osborne; Manali Bhave; Peter A. Kaufman; J. Thaddeus Beck; Luis Manso Sanchez et al.
Source: check_circle
Crossref

Data from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Data from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S1 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S1 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S2 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S2 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S3 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S3 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Supplementary Methods 1 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Supplementary Methods 1 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Table S1 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Table S1 from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

2024-09-16 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; Maria Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

Clinical and Translational Oncology
2024-08-31 | Journal article
Contributors: Luis Manso; Avinash Ramchandani-Vaswani; Ignacio Romero; Luisa Sánchez-Lorenzo; María José Bermejo-Pérez; Purificación Estévez-García; Lorena Fariña-Madrid; Yolanda García García; Marta Gil-Martin; María Quindós
Source: check_circle
Crossref

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

Breast Cancer Research and Treatment
2024-07 | Journal article
Contributors: N. Martínez-Jañez; M. Bellet Ezquerra; L. M. Manso Sanchez; F. Henao Carrasco; A. Anton Torres; S. Morales; P. Tolosa Ortega; V. L. Obadia Gil; T. Sampedro; R. Andrés Conejero et al.
Source: check_circle
Crossref

Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

Clinical Cancer Research
2024-01-05 | Journal article
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Data from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S2 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S2 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S3 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Figure S3 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Supplementary Methods 1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Supplementary Methods 1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Table S1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Table S1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

2024-01-05 | Preprint
Contributors: Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta et al.
Source: check_circle
Crossref

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Journal of Clinical Oncology
2024-01-01 | Journal article
Contributors: Funda Meric-Bernstam; Vicky Makker; Ana Oaknin; Do-Youn Oh; Susana Banerjee; Antonio González-Martín; Kyung Hae Jung; Iwona Ługowska; Luis Manso; Aránzazu Manzano et al.
Source: check_circle
Crossref

Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2023 | Journal article
Part of ISSN: 1048-891X
Contributors: Perez-Fidalgo, José Alej; ro; Guerra, Eva; García, Yol; a; Iglesias, María; Hernández-Sosa, María; Estevez-García, Purificación; Manso Sánchez, Luis; Santaballa, Ana et al.
Source: Self-asserted source
Manso Luis
grade
Preferred source (of 2)‎

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer

JNCI cancer spectrum
2023 | Journal article
Part of ISSN: 2515-5091
Contributors: Mouron, Silvana; Bueno, Maria J; Muñoz, Manuel; Torres, Raul; Rodríguez, S; ra; Apala, Juan V; Silva, Jorge; Sánchez-Bayona, Rodrigo; Manso, Luis et al.
Source: Self-asserted source
Manso Luis

Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

European journal of cancer (Oxford, England : 1990)
2023 | Journal article
Part of ISSN: 0959-8049
Contributors: Cueva, Juan F; Palacio, Isabel; Churruca, Cristina; Herrero, Ana; Pardo, Beatriz; Constenla, Manuel; Santaballa, Ana; Manso, Luis; Estévez, Purificación; Maximiano, Constanza et al.
Source: Self-asserted source
Manso Luis

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer.

Breast (Edinburgh, Scotland)
2023-07 | Journal article
Contributors: Terán S; Alva M; Tolosa P; Rey-Cárdenas M; Madariaga A; Lema L; Ruano Y; Manso L; Ciruelos E; Sánchez-Bayona R
Source: Self-asserted source
Manso Luis via Europe PubMed Central

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program.

Gynecologic oncology reports
2023-05 | Journal article
Contributors: Yubero A; Estévez P; Barquín A; Sánchez L; Santaballa A; Pajares B; Reche P; Salvador C; Manso L; Márquez R et al.
Source: Self-asserted source
Manso Luis via Europe PubMed Central

Data from Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

2023-03-31 | Preprint
Contributors: Eva Ciruelos; Patricia Villagrasa; Tomás Pascual; Mafalda Oliveira; Sonia Pernas; Laia Paré; Santiago Escrivá-de-Romaní; Luis Manso; Barbara Adamo; Eduardo Martínez et al.
Source: check_circle
Crossref

Data from Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

2023-03-31 | Preprint
Contributors: Eva Ciruelos; Patricia Villagrasa; Tomás Pascual; Mafalda Oliveira; Sonia Pernas; Laia Paré; Santiago Escrivá-de-Romaní; Luis Manso; Barbara Adamo; Eduardo Martínez et al.
Source: check_circle
Crossref

Supplementary Data from Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

2023-03-31 | Preprint
Contributors: Eva Ciruelos; Patricia Villagrasa; Tomás Pascual; Mafalda Oliveira; Sonia Pernas; Laia Paré; Santiago Escrivá-de-Romaní; Luis Manso; Barbara Adamo; Eduardo Martínez et al.
Source: check_circle
Crossref

Supplementary Data from Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

2023-03-31 | Preprint
Contributors: Eva Ciruelos; Patricia Villagrasa; Tomás Pascual; Mafalda Oliveira; Sonia Pernas; Laia Paré; Santiago Escrivá-de-Romaní; Luis Manso; Barbara Adamo; Eduardo Martínez et al.
Source: check_circle
Crossref

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

The oncologist
2022 | Journal article
Part of ISSN: 1083-7159
Contributors: Gerratana, Lorenzo; Pierga, Jean-Yves; Reuben, James M; Davis, Andrew A; Wehbe, Firas H; Dirix, Luc; Fehm, Tanja; Nolé, Franco; Gisbert-Criado, Rafael; Mavroudis, Dimitrios et al.
Source: Self-asserted source
Manso Luis

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Nature communications
2022 | Journal article
Part of ISSN: 2041-1723
Contributors: Mouron, S; Bueno, MJ; Lluch, A; Manso, L; Calvo, I; Cortes, J; Garcia-Saenz, JA; Gil-Gil, M; Martinez-Janez, N; Apala, JV et al.
Source: Self-asserted source
Manso Luis
grade
Preferred source (of 2)‎

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study

BMC cancer
2022 | Journal article
Part of ISSN: 1471-2407
Contributors: Yubero, Alfonso; Barquín, Aranzazu; Estévez, Purificación; Pajares, Bella; Sánchez, Luisa; Reche, Piedad; Alarcón, Jesús; Calzas, Julia; Gaba, Lydia; Fuentes, José et al.
Source: Self-asserted source
Manso Luis

Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2022 | Journal article
Part of ISSN: 1699-048X
Contributors: Jimeno, Rebeca; Mouron, Silvana; Salgado, Roberto; Loi, Sherene; Pérez-Mies, Belén; Sánchez-Bayona, Rodrigo; Manso, Luis; Martínez, Mario; Garrido-García, Ana; Serrano-Pardo, Rosario et al.
Source: Self-asserted source
Manso Luis

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

OncoImmunology
2022-12-31 | Journal article
Contributors: Alberto Carretero-González; Marta Hergueta-Redondo; Sara Sánchez-Redondo; Pilar Ximénez-Embún; Luis Manso Sánchez; Eva Ciruelos Gil; Daniel Castellano; Guillermo de Velasco; Héctor Peinado
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?

Cancer treatment reviews
2022-04-08 | Journal article
Source: Self-asserted source
Manso Luis
grade
Preferred source (of 2)‎

Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.

NPJ precision oncology
2022-01-27 | Journal article
Source: Self-asserted source
Manso Luis
grade
Preferred source (of 2)‎

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

The Lancet. Oncology
2021 | Journal article
Part of ISSN: 1470-2045
Contributors: Coleman, Robert L; Lorusso, Domenica; Gennigens, Christine; González-Martín, Antonio; R; all, Leslie; Cibula, David; Lund, Bente; Woelber, Linn; Pignata, S et al.
Source: Self-asserted source
Manso Luis

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

NPJ precision oncology
2021 | Journal article
Part of ISSN: 2397-768X
Contributors: Griguolo, G; Serna, G; Pascual, T; Fasani, R; Guardia, X; Chic, N; Paré, L; Pernas, S; Muñoz, M; Oliveira, M et al.
Source: Self-asserted source
Manso Luis

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

Frontiers in oncology
2021 | Journal article
Part of ISSN: 2234-943X
Contributors: Gil-Gil, Miguel J; Bellet, Meritxell; Bergamino, Milana; Morales, Serafín; Barnadas, Agustí; Manso, Luís; Saura, Cristina; Fernández-Ortega, Adela; Garcia-Martinez, Elena; Martinez-Jañez, Noelia et al.
Source: Self-asserted source
Manso Luis

Management of advanced ovarian cancer in Spain: an expert Delphi consensus

Journal of ovarian research
2021 | Journal article
Part of ISSN: 1757-2215
Contributors: Redondo, Andres; Oaknin, Ana; Rubio, Maria Jesus; Barretina-Ginesta, Maria-Pilar; de Juan, Ana; Manso, Luis; Romero, Ignacio; Martin-Lorente, Cristina; Poveda, Andres; Gonzalez-Martin, Antonio
Source: Self-asserted source
Manso Luis

Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study

Clinical cancer research : an official journal of the American Association for Cancer Research
2021 | Journal article
Part of ISSN: 1078-0432
Contributors: Turner, Nicholas C; Balmaña, Judith; Poncet, Coralie; Goulioti, Theodora; Tryfonidis, Konstantinos; Honkoop, Aafke H; Zoppoli, Gabriele; Razis, Evangelia; Johannsson, Oskar T; Colleoni, Marco et al.
Source: Self-asserted source
Manso Luis

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

ESMO Open
2021 | Journal article
EID:

2-s2.0-85117623524

Part of ISSN: 20597029
Contributors: Perez-Fidalgo, J.A.; Cortés, A.; Guerra, E.; García, Y.; Iglesias, M.; Bohn Sarmiento, U.; Calvo García, E.; Manso Sánchez, L.; Santaballa, A.; Oaknin, A. et al.
Source: Self-asserted source
Manso Luis via Scopus - Elsevier
Items per page:
Page 1 of 3